INmune Bio Inc (NASDAQ:INMB) saw a large increase in short interest in June. As of June 30th, there was short interest totalling 7,400 shares, an increase of 48.0% from the June 15th total of 5,000 shares. Based on an average trading volume of 37,900 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.
Shares of INmune Bio stock traded down $0.06 during mid-day trading on Friday, hitting $5.00. The stock had a trading volume of 69,363 shares, compared to its average volume of 47,042. The firm has a 50-day moving average of $5.62 and a two-hundred day moving average of $4.86. INmune Bio has a 12-month low of $2.20 and a 12-month high of $10.35. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.01. The firm has a market cap of $54.10 million, a P/E ratio of -6.85 and a beta of 2.41.
INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02. Sell-side analysts expect that INmune Bio will post -0.68 earnings per share for the current year.
Several analysts have recently weighed in on the stock. Maxim Group assumed coverage on shares of INmune Bio in a research note on Saturday, May 16th. They issued a “buy” rating and a $13.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up previously from $7.00) on shares of INmune Bio in a research note on Friday, May 15th.
Several hedge funds have recently modified their holdings of INMB. Financial Advocates Investment Management lifted its holdings in shares of INmune Bio by 12.8% in the 1st quarter. Financial Advocates Investment Management now owns 253,461 shares of the company’s stock worth $844,000 after acquiring an additional 28,794 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of INmune Bio by 140.4% in the 1st quarter. BlackRock Inc. now owns 15,752 shares of the company’s stock worth $52,000 after acquiring an additional 9,200 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of INmune Bio by 21.7% in the 1st quarter. Deutsche Bank AG now owns 56,048 shares of the company’s stock worth $187,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 3.17% of the company’s stock.
About INmune Bio
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Featured Article: How does a security become overbought?
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.